305 related articles for article (PubMed ID: 32223594)
21. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
[TBL] [Abstract][Full Text] [Related]
22. Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.
Mishuk AU; Fasina I; Qian J
Res Social Adm Pharm; 2020 Jun; 16(6):736-745. PubMed ID: 31445986
[TBL] [Abstract][Full Text] [Related]
23. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
24. Variation in Prostaglandin Analog Prices Paid for Through Medicare Part D.
Priluck AZ; Havens SJ
J Glaucoma; 2019 Jan; 28(1):e17-e20. PubMed ID: 30234751
[TBL] [Abstract][Full Text] [Related]
25. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
Yeung K; Dusetzina SB; Basu A
JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
[TBL] [Abstract][Full Text] [Related]
26. Association between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis.
Hohmann N; Hansen R; Garza KB; Harris I; Kiptanui Z; Qian J
Value Health; 2018 Oct; 21(10):1186-1191. PubMed ID: 30314619
[TBL] [Abstract][Full Text] [Related]
27. What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?
Hung A; Perfetto EM
J Manag Care Spec Pharm; 2016 Jul; 22(7):773-8. PubMed ID: 27348277
[TBL] [Abstract][Full Text] [Related]
28. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
[TBL] [Abstract][Full Text] [Related]
29. Effects of Medicare Part D coverage gap closure on utilization of branded and generic drugs.
Liu J; Zhang Y; Kaplan CM
Health Econ; 2023 Mar; 32(3):639-653. PubMed ID: 36399360
[TBL] [Abstract][Full Text] [Related]
30. Estimating the Direct Costs of Outpatient Opioid Prescriptions: A Retrospective Analysis of Data from the Rhode Island Prescription Drug Monitoring Program.
Aroke H; Buchanan A; Wen X; Ragosta P; Koziol J; Kogut S
J Manag Care Spec Pharm; 2018 Mar; 24(3):214-224. PubMed ID: 29485950
[TBL] [Abstract][Full Text] [Related]
31. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries.
Gross DJ; Alecxih L; Gibson MJ; Corea J; Caplan C; Brangan N
Health Serv Res; 1999 Apr; 34(1 Pt 2):241-54. PubMed ID: 10199672
[TBL] [Abstract][Full Text] [Related]
32. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
33. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
34. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
35. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
Reardon G; Schwartz GF; Mozaffari E
Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
[TBL] [Abstract][Full Text] [Related]
36. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
37. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
[TBL] [Abstract][Full Text] [Related]
38. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
39. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
Lakdawalla D; Li M
JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
[TBL] [Abstract][Full Text] [Related]
40. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
Dusetzina SB; Keating NL
J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
